- Home
- AVXL vs RERE Comparison
AVXL vs RERE Comparison
Compare AVXL & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- RERE
- Stock Information
- Founded
- AVXL 2004
- RERE 2011
- Country
- AVXL United States
- RERE China
- Employees
- AVXL N/A
- RERE N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- RERE Other Specialty Stores
- Sector
- AVXL Health Care
- RERE Consumer Discretionary
- Exchange
- AVXL Nasdaq
- RERE Nasdaq
- Market Cap
- AVXL 956.7M
- RERE 932.6M
- IPO Year
- AVXL N/A
- RERE 2021
- Fundamental
- Price
- AVXL $9.80
- RERE $4.26
- Analyst Decision
- AVXL Strong Buy
- RERE
- Analyst Count
- AVXL 2
- RERE 0
- Target Price
- AVXL $44.00
- RERE N/A
- AVG Volume (30 Days)
- AVXL 1.2M
- RERE 1.5M
- Earning Date
- AVXL 08-12-2025
- RERE 11-19-2025
- Dividend Yield
- AVXL N/A
- RERE N/A
- EPS Growth
- AVXL N/A
- RERE N/A
- EPS
- AVXL N/A
- RERE 0.12
- Revenue
- AVXL N/A
- RERE $2,588,775,650.00
- Revenue This Year
- AVXL N/A
- RERE $30.66
- Revenue Next Year
- AVXL N/A
- RERE $25.12
- P/E Ratio
- AVXL N/A
- RERE $35.70
- Revenue Growth
- AVXL N/A
- RERE 27.39
- 52 Week Low
- AVXL $5.03
- RERE $2.00
- 52 Week High
- AVXL $14.44
- RERE $4.93
- Technical
- Relative Strength Index (RSI)
- AVXL 58.71
- RERE 45.42
- Support Level
- AVXL $8.80
- RERE $4.50
- Resistance Level
- AVXL $10.04
- RERE $4.78
- Average True Range (ATR)
- AVXL 0.49
- RERE 0.22
- MACD
- AVXL 0.18
- RERE -0.05
- Stochastic Oscillator
- AVXL 73.79
- RERE 15.83
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.